KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) EBIAT (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of EBIAT data on record, last reported at $49.6 million in Q4 2025.

  • For Q4 2025, EBIAT rose 315.57% year-over-year to $49.6 million; the TTM value through Dec 2025 reached $115.5 million, up 325.74%, while the annual FY2025 figure was $127.9 million, 273.17% up from the prior year.
  • EBIAT reached $49.6 million in Q4 2025 per AMRX's latest filing, up from $18.1 million in the prior quarter.
  • Across five years, EBIAT topped out at $49.6 million in Q4 2025 and bottomed at -$240.1 million in Q2 2022.
  • Average EBIAT over 5 years is -$10.9 million, with a median of $11.8 million recorded in 2023.
  • The widest YoY moves for EBIAT: up 1134.42% in 2023, down 1199.26% in 2023.
  • A 5-year view of EBIAT shows it stood at -$14.8 million in 2021, then surged by 60.67% to -$5.8 million in 2022, then plummeted by 1199.26% to -$75.6 million in 2023, then soared by 115.78% to $11.9 million in 2024, then surged by 315.57% to $49.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $49.6 million in Q4 2025, $18.1 million in Q3 2025, and $35.6 million in Q2 2025.